CLINICAL_TRIALS ClinicalTrials.gov record update

Clinical Study of 18F Labeled Probe Targeting Fibroblast Activation Protein Inhibitor and Integrin Avβ3 (FAPI-RGD) in Ovarian Cancer,comparison with 18F-FDG

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06614062
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:11.178713+00:00
Published At: 2024-09-26T00:00:00+00:00
Record Updated At: 2024-09-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Observational"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-09-26"
protocolSection.identificationModule.nctId: "NCT06614062"
protocolSection.identificationModule.officialTitle: "Clinical Study of 18F Labeled Probe Targeting Fibroblast Activation Protein Inhibitor and Integrin Av\u03b23 (FAPI-RGD) in Ovarian Cancer,comparison with 18F-FDG"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.